The day in pharma, read in minutes.
NewsOnconetix Acquisition Target Realbotix Secures Streaming Series Appearance for Humanoid Robot
Realbotix, Onconetix's pending acquisition target, secures a streaming series deal as its humanoid robots expand across healthcare, education, and entertainment.
Lantheus Signs $8 Billion Merger with Curium to Build 70-Country Radiopharmaceutical Network
Roivant Targets September 2026 Brepocitinib Launch Following Dermatomyositis Commercial Preparations
Priovant Launches Phase 3 BEACON+ Trial of Brepocitinib in Cutaneous Sarcoidosis After FDA Breakthrough Designation
Harrow Acquires Global TYRVAYA Rights from Viatris, Including Pending MAAs Across Multiple Markets
Latest news
11 storiesTarsus Pharmaceuticals Acquires Alkeus Pharmaceuticals to Advance Stargardt Disease Oral Therapy
Tarsus acquires Alkeus, adding Phase 3 gildeuretinol for Stargardt disease and triggering GMP scale-up and NDA strategy work.
Allergan Aesthetics Files sNDA for BOTOX Cosmetic Jawline Indication with FDA
Allergan Aesthetics files sNDA with FDA to expand BOTOX Cosmetic labeling to include a jawline contouring indication.
Lexicon Pharmaceuticals Nears NDA Resubmission for ZYNQUISTA in Type 1 Diabetes Following FDA-Defined Safety Threshold
Lexicon's ZYNQUISTA NDA resubmission nears completion as STENO1 safety data approach FDA-defined thresholds; Q4 2026 filing targeted.
Ascendis Pharma Achieves Week 78 COACH Milestone as YUVIWEL Tops 170 U.S. Enrollments
Ascendis Pharma completes reACHin Trial enrollment for infant achondroplasia while COACH Week 78 data and YUVIWEL uptake signal expanding regulatory and manufacturing scope.
Propanc Biopharma Achieves Over 90% Tumor Growth Inhibition for PRP in PDAC Preclinical Models
Propanc Biopharma reports >90% tumor growth inhibition for PRP in PDAC models, with GMP production and a Phase 1b CTA filing targeted for late 2026.
FDA Signals Enforcement Shift on Unapproved Desiccated Thyroid Extract Products Used by 1.5 Million Patients
FDA notifies DTE manufacturers of forthcoming compliance and development guidance, raising NDA submission urgency for 1.5 million-patient market.
3PBIOVIAN Achieves GMP Manufacturing Milestone in PITÁGORAS Personalized TCR Therapy Program
3PBIOVIAN establishes GMP manufacturing protocols for AI-identified TCR candidates within the €1.6M PITÁGORAS personalized immunotherapy consortium.
Sight Sciences Receives FDA Clearance For OMNI Ultra Surgical System To Treat Glaucoma
Sight Sciences receives FDA clearance for its OMNI Ultra Surgical System, an implant-free MIGS device for treating open-angle glaucoma.
Editas Medicine Appoints Dr. Patrick Ellinor To Board Of Directors
Editas Medicine appoints cardiovascular genetics expert Dr. Patrick Ellinor to its Board as it advances its gene editing pipeline including EDIT-401.
IQVIA And Medera Partner To Advance Cardiac Gene Therapy And Human-Based Drug Discovery
IQVIA partners with Medera to accelerate cardiac gene therapy development and human-based drug discovery through Sardocor and Novoheart.
Applied Biologics Begins AATB Reaccreditation Process To Maintain High Tissue Banking Standards
Applied Biologics begins its AATB reaccreditation process, marking nearly a decade of continuous tissue banking accreditation for XWRAP.
Worth your time this week
ClinNEXUS Appoints John Stamatopoulos As Chief Growth Officer To Drive Strategic Expansion
Silexion Therapeutics Reports New Preclinical Data Supporting SIL204 Combination With Immunotherapy In KRAS-Driven Cancers
Capra Biosciences Secures Additional ASPR Funding To Expand Domestic API Manufacturing Program
